NLS Pharmaceutics (NASDAQ:NCEL) Shares Down 1.8% – Should You Sell?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) shares dropped 1.8% during trading on Monday . The company traded as low as $3.16 and last traded at $3.25. 14,509 shares were traded during mid-day trading, an increase of 11% from the average session volume of 13,085 shares. The stock had previously closed at $3.31.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Laidlaw initiated coverage on NLS Pharmaceutics in a research report on Monday, July 13th. They set a “buy” rating and a $23.00 price objective on the stock. Weiss Ratings upgraded NLS Pharmaceutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, NLS Pharmaceutics presently has an average rating of “Hold” and an average price target of $23.00.

NLS Pharmaceutics Stock Performance

The company’s 50 day moving average price is $3.57 and its 200-day moving average price is $3.12.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.